Kengreal

Chemical Namecangrelor
Dosage FormInjection (intravenous; 50 mg/ 10 mL)
Drug ClassInhibitors
SystemCardiovascular
CompanyChiesi USA Inc
Approval Year2015

Indication

  • Indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
Last updated on 10/13/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Kengreal (cangrelor) Prescribing Information 2019Chiesi USA, Inc., Cary, NC